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The effects of intravenous elgodipine, a new sec- 
ond-generation dihydropyridtne calcium antago- 
nist, on hemodynamics and coronary artery diam- 
eter were investigated in 15 patients undergoing 
cardiic catheterixation for suspected coronary ar- 
tery disease. Despite a significant decrease in sys- 
temic blood pressure, elgodipine infused at a rate 
of 1.5 ccg/hg/min over a pertod of 10 minutes did 
not affect heart rate and kft ventrkutar end-dia- 
stdic pressure. The contractile responses during 
isovolumic contraction showed a slight but dgnifi- 
cant increase in maximum vetocity (56 f 10 to 60 
f 10 seconds-‘; p <O.OOS), whereas the time con- 
stant of early relaxation was shortened from 49 f 
11 to 44 f a ms (p <O.OS). Coronary stnus and 
great cardiac vein flow increased significantly by 
15 and 2696, respecttvety. As mean aortic pres- 
sure decreased, a significant decrease in coronary 
shtus (-27%) and great cardiac vein (-28%) resis- 
tance was observed, white the calculated myocar- 
dial oxygen consumption remained unchanged. In 
all, 69 coronary segments (including 13 stenotic 
segments) were analyzed quantitatively using 
computer-asststed quantitative coronary angiogra- 
phy. A stgnificant imrease in mean coronary ar- 
tery diameter (2.27 f OS3 to 2.46 f 0.53 mm; p 
<O.OOOOOl), as well as in obstruction diameter, 
(1.08 f 0.29 to 1.36 f 0.32 mm; p <0.02), was 
observed. The resutts demonstrate that elgodi- 
pine, in the route and dose described, induces sig- 
n&ant vasodilatation of both coronary resistance 
and epicardial conductance vessels, without ad- 
verse effects on heart rate, myocardial oxygen de- 
mand and contractile indexes. 
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lgodipine (isopropyl (2-(N-methyl-N-(4-fluoro- E benzyl)-amine)-ethyl, 2,6-dimethyl-4-(2’,3’-meth- ylenedioxypheynl)-1,4-dihydropyridine-3,5-dicar- 
boxylate, monohydrochloride) is a newly synthesized 
drug with calcium entry blocking properties belonging 
to the second generation of the phenyldihydropyridine 
group.iy2 In vitro studies have shown that the drug ap 
pears to be loo-fold more potent in inducing vasodilata- 
tion than in causing negative inotropic effects’ and that 
when comparing different vascular beds, the most pro- 
nounced vasodilatory effect was in the coronary vascu- 
lature.3 This relative selectivity of elgodipine for the cor- 
onary vascular bed may be of particular significance in 
patients with coronary artery disease where an im- 
balance in myocardial oxygen supply and demand is 
caused by decrease in the coronary artery luminal diam- 
eter. Animal studies3,4 have demonstrated that elgodi- 
pine is a potent vasodilator, decreasing blood pressure 
and total peripheral resistance, and increasing cardiac 
output and coronary blood flow dose-dependently, with 
little effect on heart rate. The potency of elgodipine in 
reducing systemic vascular resistance is slightly leas 
than that of nifedipine, nisoldipine and nimodipine, but 
considerably greater (lO- to 50-fold) than that of bepri- 
dil, nicorandil and pimobendan.3 These effects of elgodi- 
pine on systemic and coronary hemodynamics have yet 
to be evaluated in patients with coronary artery disease. 
The present study investigates the effects of intravenous 
elgodipine on coronary and left ventricular hemody- 
namics, and assesses quantitatively the vasodilatory ac- 
tion of elgodipine on both stenotic and nonstenotic oro- 
nary arteries, using computer-assisted quantitative cor- 
onary angiography. 
METHODS 
Patknk The study comprised 15 patients (12 men 
and 3 women, mean age 57 years, range 40 to 69) who 
underwent cardiac catheterization for the investigation 
of suspected coronary artery disease. All patients were 
in sinus rhythm with no signs of cardiac failure and 
gave informed consent o participate in the study. Pa- 
tients with unstable angina and acute myocardial in- 
farction were excluded from the study. Clinical and an- 
giographic data are listed in Table I. 
Protecob All medication was discontinued 148 
hours before the study. Cardiac catheterization was per- 
formed through the femoral artery and vein. Patients 
fasted and were not given premeditation. No drug (oth- 
er than 50 mg of intravenous heparin) was administered 
during the study. After a thermodilution flow catheter 
was inserted in the coronary sinus and great cardiac 
vein, angiography of the right and left coronary artery 
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TABLE I Clinical Characteristics 
Coronary Artery 
Narrowed > 50% 
in Diameter 
Age (yr) EF 
Pt. & Sex NYHA PMI (%) LAD LC Right 
1 43F II 0 70 0 0 + 
2 66M Ill Anterior 49 + + + 
3 68M II 0 50 + + + 
4 64M I Inferior 41 + 0 + 
5 55M II 0 62 0 + 0 
6 63M II 0 77 0 + + 
7 40M II Anterior 67 + 0 0 
8 44M II Anterior - + 0 0 
9 60M II Inferior - + + + 
10 59M II Anterior 62 + 0 0 
11 51F II 0 65 0 0 0 
12 64M Ii Inferior 66 + + + 
13 69F II 0 64 + 0 0 
14 44M II Inferior 55 + + + 
15 62M II Anterolateral 71 0 + 0 
EF = global ejection fraction; LAD = left anterior descending; LC = left circumflex; 
NYHA = New York Heart Association classifications; PMI = previous myocardial 
infarction. 
was performed in standard views including cranial and 
caudal angulations. The geometry of the x-ray gantry, 
and the kilovolts and milliamperes of the x-ray genera- 
tor were obtained and recorded on-line for each angio- 
gram. A dual-tip micromanometer catheter was then 
positioned in the left ventricle. Ten minutes after cathe- 
ter instrumentation, baseline left ventricular and aortic 
pressures, pressure-derived indexes of isovolumic con- 
traction and relaxation, and thermodilution coronary si- 
nus and great cardiac vein flows were measured on-line 
at spontaneous heart rate. Oxygen saturations were ob- 
tained simultaneously from the aorta, coronary sinus 
and great cardiac vein. Elgodipine was then adminis- 
tered intravenously at a rate of 1.5 pg/kg/min over a 
period of 10 minutes, and all measurements were re- 
peated at 5, lo,20 and 30 minutes. Angiography of the 
left coronary artery was repeated at 10 and 30 minutes 
in all projections, corresponding to those used during 
baseline angiography. All angiograms were obtained us- 
ing the Judkins technique and recorded on Kodak 35 
mm cinefilm at a rate of 25 frames/second. Nonionic 
contrast medium was injected manually. 
Hemodynamk determinations: Left ventricular pa- 
rameters were measured at spontaneous heart rate using 
the dual-tip micromanometer catheter, where 112 
heart beats were processed and averaged on-line by 
means of the representative b at method in a dedicated 
computer system.5,6 The following left ventricular pres- 
sure-derived indexes of isovolumic ontraction and re- 
laxation were computed: peak left ventricular pressure, 
end-diastolic pressure, peak first derivative of left ven- 
tricular pressure (dP/dt), peak left ventricular dP/dt/p 
from total pressure providing p >20 mm Hg (peak 
Vcn), dP/dt/p linearly extrapolated to 0 mm Hg 
(Vmax), and the time constants for early relaxation 
(Tau), a semilogarithmic biexponential fit of the left 
ventricular pressure decay characterized by 2 exponen- 
tial time constants: Taul for the first 40 ms, and Tau2, 
the fit after the first 40 ms.7 Mean aortic pressure was 
determined by digital integration. 
Coronary venous blood flow measurements and cal- 
eulations: Coronary sinus and great cardiac vein blood 
flows were measured on-line using a constant infusion 
thermodilution technique. Arterial, coronary sinus and 
great cardiac vein oxygen saturations were measured 
FIGURE 1. One cineframe of distal left cir- 
aanllox (CX-Dim) corenaryartsrylncau- 
dol(CA)projsc6onlsd10wnwlthdetecM 
cmtoursand~ functiens superim- 
-,refarmce 
awe expmssed In miWimehr8. In 
MS case, rofemme dlomstsr is 4.03 mm, 
aEamebr Is 2.16 mm, cor- 
ammeter stenosis (PSTEN) 
of Sl%, and area stenosis (A-MEN) of 
76%. PTCA = percutaneous tranduminal 
-ry-rty. 
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TABLE II Effects on Systemic and Left Ventricular Hemodynamics 
5 10 20 30 
Baseline Minutes Minutes Minutes Minutes 
Heart rate (beatslmin) 70 f 10 73 + 11 75 + 14 73 k 18 70 f 12 
Systolic aortic pressure (mm Hg) 145 + 24 130 + 24* 123 * 22* 140 lr 32 138 +- 23 
Diastolic aortic pressure (mm Hg) 70 2 9 65 2 9$ 61 +8* 69* 15 70 + 11 
Mean aortic pressure (mm Hg) 982 15 90 * 15* 86 e 14’ 97 k 23 97 + 14 
Left ventricular systolic pressure 139 + 22 126 + 22* 117 2 20f 133 -t 29 133 * 21t 
(mm Hg) 
End-diastolic (mm Hg) pressure 13 -+ 3 12 +4 13 2 4 13 ? 4 12 -t 5 
Peak VCE (secrl) 39 2 9 42 zt 12 42 + 13 39 k 10 39 * 9 
Vmax (set-‘1 56 t 10 57 2 9 60 k lO$ 57 k 10 54 + 9 
Positive dP/dt (mm Hgsec-I) 1,485 2 308 1,467 + 319 1,496 t 396 1,565 -t 489 1,453 2 308 
Negative dP/dt (mm Hg w-1) 1,743 ?z 354 1,673 ? 350t 1,637 + 359$ 1,727 2 383 1,712 2 358 
Taul (ms) 49 2 11 46 f 8t 44 2 9t 472 11 48+ 11 
*p <0.00005; tp 10.05; tp <O.O05vs baseline. 
Values are expressed as mean ? SD. 
dP/dt = rate of change I” left ventricular pressure: Peak VCE = peak measured velocity of contractile element; Tat11 = time constant of early relaxation; Vmax = VCE linearly 
extrapolated to 0 mm Hg. 
spectrophotometrically, and oxygen content was calcu- 
lated. Global (coronary sinus) and regional (great cardi- 
ac vein) myocardial oxygen consumptions were calcu- 
lated as the product of coronary venous blood flow and 
arteriocoronary venous oxygen content difference. Glob- 
al and regional coronary vascular resistances were de- 
rived from the ratio of mean aortic pressure to coronary 
venous flow. 
Quantitative coronary angiography: Quantitative 
analysis of selected coronary segments was performed 
with the computer-assisted cardiovascular angiography 
analysis system that was described in detail previous- 
ly- *v9 Briefly, to analyze a coronary arterial segment in a 
selected frame of 35 mm cinefilm, an optically magni- 
fied portion of the image encompassing that segment is 
converted into video format by means of a cinevideo 
converter. The contours of the vessels are detected auto 
matically on the basis of the weighted sum of first 
and second derivative functions applied to the digitiz- 
ed brightness information. Calibration of the diameter 
data of the vessels in absolute values (mm) is achieved 
using the angiographic atheter filmed empty of con- 
trast. To this end, the contours of a user-defined portion 
of the optimally magnified catheter are detected auto- 
matically and corrected for pincushion distortion caused 
by the image intensifier. From the contours, vessel di- 
ameter functions (in absolute mm) are determined by 
computing the shortest distances between the left and 
right contour positions. A representative analysis with 
the detected contours and diameter functions superim- 
posed on the original video image is shown in Figure 1. 
For nonobstructed coronary segments, the mean diame- 
ter of the analyzed segment was computed. For ob- 
structed segments, the minimal obstruction diameter 
was assessed. Average values for baseline, and lo- and 
20-minute angiograms obtained from 12 orthogonal 
angiographic views were compared. 
-ticai w--gradient- stenotic le- 
sionsr For obstructed coronary segments, the theoretical 
pressure gradients across the stenotic lesion at theoreti- 
cal coronary flow rates of 1, 2 and 3 ml/s were calcu- 
lated using the data obtained at quantitative angio 
graphic analysis according to an accepted formula’0Ji: 
Porno = Q - (Rp + Q * Rr), where Pox~n is the theo- 
retical pressure reduction (mm Hg) across the stenosis, 
Q is the mean coronary blood flow (ml/s), Rp is the 
Poiseuille resistance, and R-r is the turbulent resistance. 





x (length obstruction) x r 
(obstruction area)’ 
where Ci = 8 X (blood viscosity), with blood viscosi- 





RT = C, x obstruction area - normal distal area 
where C2 = blood density/0.266, with blood density 
= 1.0 (g/cm3). This assessment of pressure gradients 
was used and described in our previous tudies.i2-I4 
Statirtieal analysis: Results are expressed as mean 
f SD. The data was subjected to analysis of variance 
for repeated measurements, and when significant differ- 
ences were apparent, further comparisons were made 
with Student’s paired t test. A p value <0.05 was con- 
sidered significant. 
RESULTS 
Systemic hemdynamies: The systemic responses 
after intravenous administration of elgodipine at a rate 
of 1.5 rg/kg/min over 10 minutes are listed in Table II. 
At spontaneous heart rate, elgodipine produced asignif- 
icant decrease in aortic pressure, while heart rate did 
not change significantly. During elgodipine infusion, left 
ventricular systolic pressure decreased significantly by 
16% (p <O.OOOOS), while end-diastolic pressure re- 
mained unchanged (Table II). Although the increase in 
peak Vca did not reach statistical significance, Vmax 
was significantly increased (56 f 10 to 60 f 10 sec- 
onds-‘; p <O.OOS), whereas Taul was shortened (49 f 
11 to 44 f 9 ms; p <0.05). At 20 minutes, all parame- 
ters were no longer significantly different from baseline. 
Coronary hendynamics: After elgodipine infusion, 
coronary sinus and great cardiac vein blood flows in- 
creased significantly (75 f 26 to 86 f 30 ml/r&r [p 
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TABLE III Effects on Coronary Hemodynamics 
5 10 20 30 
Baseline Minutes Minutes Minutes Minutes 
Coronary sinus flow (ml/min) 75 2 26 81 * 30* 86 + 30t 83 -c 27$ 81 t 2at 
Great cardiac vein flow Iml/min) 34 -c 10 38 2 13$ 43 2 13* 39 + 12 36 1 10 
Oxygen difference (aortocoronary sinus) (ml%) 13.9 k 1.7 13.1 2 1.5* 11.9 k 1.54 12.4 f 1.5* 13.2 2 1.3* 
Oxygen difference (aorta great cardiac vein) (ml%) 13.9 5 1.7 13.2 + 1.5* 12.0 2 1.5t 12.5 I?: l.l* 13.0 5 1.4* 
Global myocardial consumption (ml/min) oxygen 10.2 f 3.0 10.4 f 3.4 10.1 f 3.3 10.3 2 3.4 10.5 2 3.3 
Regional myocardial oxygen consumption Iml/min) 4.8 r 1.2 5.1 2 1.5 5.2 r 1.5 5.1 t 1.6 4.7 2 1.1 
Coronary sinus resistance (mm Hg/ml/min) 1.5 k 0.5 1.3 -c 0.5t 1.1 * 0.35 1.3 2 0.4$ 1.3 5 0.5 
Great cardiac vein resistance (mm Hg/ml/min) 3.2 2 1.4 2.7 2 1.4* 2.3 + 1.2t 2.7 k 1.1s 3.0 2 1.3 
l p ~0.005; tp <0.0005; tp ~0.05; §p <O.O0005vs baseline. 
Values are expressed as mea” * SO. 
TABLE IV Effects on Absolute Coronary Artery Diameter (mm) in All Analyzed Segments I 
I Coronary 10 P 30 P Artery Segment Baseline Minutes Value* Minutes Value* 
Left anterior descending 
Proximal (n = 15) 2.46 2 0.50 2.69 2 0.50 0.004 2.57 + 0.47 0.06 
Mid (n = 11) 2.53 f 0.58 2.99 t 0.52 0.05 2.67 2 0.52 0.07 
Distal (n = 14) 1.81 f 0.27 2.03 f 0.31 0.03 1.93 2 0.28 0.03 
Left circumflex artery 
Proximal (n = 15) 2.51 ‘- 0.51 2.55 f 0.45 0.1 2.64 f 0.48 0.004 
Distal (n = 14) 2.06 k 0.38 2.28 -t 0.43 0.0005 2.17 f 0.42 0.04 
Total tn = 69) 2.27 k 0.53 2.48 r+ 0.53 0.000001 2.39 r 0.52 0.000001 
‘Versus baseline. 
Values are expressed as mean + SO. 
I I 
TABLE V Effects on Stenotic Segments (n = 13) 
10 P 30 P 
Baseline Minutes Value* Minutes Value* 
Obstruction length (mm) 5.09 + 2.12 5.32 -t 1.59 0.9 4.77 -t 1.25 0.1 
Obstruction diameter (mm) 1.08 2 0.29 1.36 + 0.32 0.02 1.26 + 0.33 0.03 
Obstruction area (mm2) 0.99 k 0.67 1.56 t 0.84 0.03 1.24 f 0.77 0.09 
Diameter stenosis (%I 58 + 6 49 k 8 0.008 52 f 10 0.05 
Area stenosis (%I 85 e 9 782 16 0.08 83 f 13 0.5 
Reference diameter (mm) 2.51 k 0.52 2.72 f 0.64 0.09 2.63 -+ 0.44 0.05 
Reference area (mmz) 5.13 * 1.98 6.11 + 2.69 0.1 5.58 A 1.70 0.08 
Symmetry index 0.64 + 0.18 0.59 -+ 0.20 0.9 0.56 zk 0.22 0.2 
*Versus baseline. 
Values are expressed as mean 2 SD. 
<0.0005], and 34 f 10 to 43 f 13 ml/mm [p <O.OOS], 
respectively; Table III). As mean aortic pressure de- 
creased from 98 f 15 to 86 f 14 mm Hg (p < 
0.00005), the calculated global and regional coronary 
vascular esistances decreased significantly (1.5 f 0.5 to 
1.1 f 0.3 mm Hg/ml/min [p <0.00005], and 3.2 f 1.4 
to 2.3 f 1.2 mm Hg/ml/min [p <O.OOOS], respective- 
ly). Although the differences in mean arteriocoronary 
sinus and arterio-great cardiac vein oxygen contents 
decreased from 13.9 f 1.7 to 11.9 f 1.5 ml% (p 
<0.00005) and from 13.9 f 1.7 to 12.0 f 1.5 ml% (p 
<0.0005), respectively, the global and regional myocar- 
dial oxygen consumptions remained unchanged. 
QwnWathrecoronary anglograms: In all, 69 coro- 
nary segments (including 13 stenotic segments) of the 
left coronary artery were analyzed. The individual 
changes in absolute diameter (mm) of all coronary 
segments as measured uring the 3 consecutive angio- 
grams are listed in Table IV. Mean coronary diameter 
increased significantly from 2.27 f 0.53 to 2.48 f 
0.53 mm (p <O.OOOOOl) at 10 minutes and to 2.39 f 
0.52 mm (p <O.OOOOOl) at 30 minutes after initiation 
of drug infusion. 
Data for the 13 stenotic segments are listed in Table 
V. Mean obstruction diameter increased significantly 
from 1.08 f 0.29 to 1.36 f 0.32 mm (p <0.02) at 10 
minutes and to 1.26 f 0.33 mm (p <0.03) at 30 min- 
utes after drug infusion was begun, whereas diameter 
stenosis decreased from 58 f 6 to 49 f 8% (p <0.008) 
and to 52 f 10% (p <0.05), respectively. Consequently, 
assuming theoretical coronary flows of 1, 2 and 3 ml/s, 
the theoretical pressure gradients across the 13 stenotic 
lesions decreased significantly after elgodipine infusion 
(Figure 2). 
DISCUSSION 
The results of this study of patients with coronary 
artery disease confirm for the first time the beneficial 
effects of elgodipine, a newly synthesized ihydropyri- 
dine calcium antagonist, on systemic and coronary he- 
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ments.J*4 
Meets on he& rate: Several studies in anesthetized 
animals3 showed that elgodipine is a potent systemic 
and coronary vasodilator, decreasing blood pressure and 
total peripheral resistance in a dose-dependent manner 
associated with an increase in coronary blood flow, 
whereas heart rate does not change or may even de- 
crease in response to higher doses (60 pg/kg). There- 
fore, it is likely that (as observed with nimodipine)15 
elgodipine possesses some negative chronotropic activi- 
ty’ that counteracts reflex tachycardia. However, it 
should be appreciated that reflex tachycardia can be at- 
tenuated by anesthetic agents, reducing thii phenome- 
non in anesthetized animals. To establish the cardiovas- 
cular profile of elgodipine, free of the potential influence 
of anesthetic agents, van Woerkens et al4 investigated 
its effects in conscious instrumented pigs and observed a 
marked increase in heart rate, as well as in cardiac out- 
put and dP/dtmax. Although large doses of elgodipine 
were used, this may suggest hat anesthesia in earlier 
studies blunted a reflex-mediated tachycardia. How- 
ever, despite anesthesia, nisoldipine increases heart rate 
at a dose producing an equivalent reduction in systemic 
pressure.16 Furthermore, when elgodipine is adminis- 
tered to conscious pigs after /3-adrenoceptor blockade 
with propranolol, positive chronotropic and inotropic ef- 
fects are substantially reduced, although an increase in 
heart rate is not completely eliminated4 This proprano- 
lol-resistant achycardia is not unique to elgodipine, as 
it has also been observed for other dihydropyridines and 
vasodilators*7-22 and suggests a withdrawal of parasym- 
pathic tone. 
modynamics previously suggested by animal experi- _ 1 
In the present study, despite a marked decrease in 
aortic pressure, only a slight increase in heart rate was 
observed and this did not reach statistical significance 
L 
w Flow-3 ml/s 
\ 
-+- Flow-2 ml/s 
,+ Flow=1 ml/s 




(Table II). Although all cardiac medication (including 
&blocking agents) was discontinued in all patients 148 
hours before the study it may be speculated that @-adre- 
noceptor blockade could persist beyond this time and 
contributed to the lack of effect on heart rate. However, 
the resting heart rates of our study population suggest 
minimal B-blockade ffect at the initiation of the study. 
Effaets on inotropie state: In vitro studies have 
shown that elgodipine appears to be lOO-fold more po- 
. r = -0.64 
p< 10-6 
-20 I I I 1 1 
0 1 2 3 4 
baseline coronary artery diameter (mm) 
f1 
i i, --- l--j-- 0 





Coronary artery segments 
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tent as a vasodilator than as a negative inotrope.’ In 
conscious animals, elgodipine produces dose-related in- 
creases in cardiac output and dP/dtmax, while left ven- 
tricular end-diastolic pressure (as with other dihydro- 
pyridines)i7 remains unchanged.4 In conscious pigs with 
a 3- to 4-week-old myocardial infarction, the vasodilator 
responses to elgodipine are similar, although accompa- 
nied by considerably less of an increase in dP/dtmax 
compared with the effects in normal animals, but left 
ventricular end-diastolic pressure decreases signiticant- 
ly.4 In the present study, elgodipine infusion led to a 
slight but significant increase in Vmax (Table II). Be- 
cause heart rate and left ventricular end-diastolic pres- 
sure were unaffected, it may be suggested that, as used 
in the present study, the compound oes not exert nega- 
tive inotropic actions. However, our approach using iso- 
volumic indexes could not entirely exclude the possibili- 
ty of some negative inotropism. Furthermore, because 
elgodipine does not possess any Badrenomimetic ef- 
fects, this relatively positive inotropic response to the 
drug is probably not an intrinsic property of this new 
calcium antagonist, but rather related to its ability to 
induce peripheral vasodilation and reduce impedance to 
left ventricular ejection. 
However, the absence of a negative inotropic effect 
of elgodipine is even more evident during intracoronary 
infusion3; 0.3 pg/kg/min substantially dilated the coro- 
nary vascular bed, but had only a minor effect on re- 
gional contractile function, whereas negative inotropic 
effects only became apparent at a rate of 0.9 pg/ 
kg/mm, which also affected systemic responses. Admin- 
istered intravenously, a 30-fold greater dose would be 
needed to produce a negative inotropic effect, almost 20 
times the dose administered in our study. Realistically, 
such a dose would not be clinically appropriate, because 
of the likelihood of severe hypotension. 
Effects on isovolumic relaxation: Experimental 
work has emphasized the role of calcium influx-efflux 
in regulating the relaxation of the myocardial cell.23 
Left ventricular isovolumic relaxation is often abnor- 
mally prolonged in patients with coronary artery dis- 
ease,7.24.25 probably due to the presence of fibrotic scar 
tissue or still viable myocardium in which the biochemi- 
cal process of activation (contraction and relaxation) 
has been altered by chronic ischemia.25,26 Because it has 
been demonstrated that myocardial ischemia leads to 
asynergy of wall motion that can have a major role in 
altering the time course of the isovohunic pressure re- 
duction,26+27 it may be expected that an improvement of 
the asynergic zones would result in a more synchronous 
and rapid relaxation of the whole ventricle. In our 
study, Taul was significantly shortened after intrave- 
nous infusion of elgodipine (Table II). However, these 
results do not necessarily imply the intrinsic improve- 
ment of relaxation, but may be the indirect effects of a 
significant decrease in end-systolic pressure and volume. 
EffeCtSOIl eeswuuy vi: Animal work 
has shown that intravenous elgodipine dose-dependently 
increases myocardial blood flow, with the greatest in- 
crease (up to 30%) occurring in the subepicardial layer.3 
In the presence of a simultaneous decrease in perfusion 
pressure, vasodilatation occurs in all layers of the myo- 
cardium to produce the necessary decrease in coronary 
vascular resistance, the decrease in the subepicardium 
(45%) being more pronounced than that (30%) in the 
subendocardium.3 The present study confirms that elgo- 
dipine is a potent coronary vasodilator in humans. Coro- 
nary sinus and great cardiac vein flows increased signif- 
icantly during elgodipine infusion by 15 and 26%, re- 
spectively. As mean aortic pressure dropped, substantial 
decreases in global (-27%) and regional (-28%) coro- 
nary vascular esistances were observed. The increase in 
coronary venous flow was associated with an increase in 
coronary venous oxygen saturation, resulting in a de 
crease in arteriocoronary venous oxygen content differ- 
ence such that the calculated myocardial oxygen con- 
sumption did not decrease significantly (Table III). 
These results are consistent with our previous study of 
the effects of intravenous nisoldipine.28 
alantitathfe eoro~ry angiography: To increase the 
accuracy of diameter measurements and to better re 
fleet the true luminal cross-sectional rea, multiple an- 
giographic views (12 orthogonal) were obtained in our 
study. If a coronary segment is nonaxisymmetric, vaso- 
dilation may accentuate the asymmetry of the lumen by 
preferentially relaxing the nonatherosclerotic part of the 
arterial wall. Consequently, the use of 1 angiographic 
view would be misleading. A relatively limited number 
of stenotic lesions was analyzed in this study owing to 
the following: (1) Selection needed high technical quali- 
ty angiograms with clear views of the pre- and poststa 
notic segments; (2) orthogonal projections of the stenot- 
ic lesions were necessary; and (3) repeated angiography 
was limited to the left coronary artery. 
Our results indicate that elgodipine induces signili- 
cant vasodilatation ot only in normal but also in 
stenotic coronary segments (Tables IV and V). The 
increase in the diameter of the nonstenotic segments 
was more pronounced in the distal and smaller sized 
segments than that in the larger proximal ones (Figure 
3) as was previously observed with other vasodilatory 
agents.29y30 Furthermore, the theoretical pressure gradi- 
ents across the stenotic lesions (computed from the data 
obtained at quantitative coronary angiography) showed 
a considerable decrease after elgodipine administration 
(Figure 2). 
Clinical implicetiens: At the dose used in the present 
study, elgodipine did not produce any untoward effects 
and was consistently beneficial in terms of coronary he 
modynamics. Therefore, elgodipine is of potential value 
for the treatment of ischemic heart disease and hyper- 
tension. Furthermore, the apparent absence of negative 
inotropic effects, and the reduction of cardiac afterload 
without an increase in preload are perhaps of particular 
relevance to the treatment of patients with mild to mod- 
erate congestive heart failure. 
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